Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. / Larsen, Camilla Bøgelund; Winther, Kristian Hillert; Cramon, Per Karkov; Rasmussen, Åse Krogh; Feldt-Rasmussen, Ulla; Knudsen, Nils Jakob; Bjorner, Jakob Bue; Schomburg, Lutz; Demircan, Kamil; Chillon, Thilo Samson; Gram, Jeppe; Hansen, Stinus Gadegaard; Brandt, Frans; Nygaard, Birte; Watt, Torquil; Hegedüs, Laszlo; Bonnema, Steen Joop.
In: European Thyroid Journal, Vol. 13, No. 1, e230175, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism
AU - Larsen, Camilla Bøgelund
AU - Winther, Kristian Hillert
AU - Cramon, Per Karkov
AU - Rasmussen, Åse Krogh
AU - Feldt-Rasmussen, Ulla
AU - Knudsen, Nils Jakob
AU - Bjorner, Jakob Bue
AU - Schomburg, Lutz
AU - Demircan, Kamil
AU - Chillon, Thilo Samson
AU - Gram, Jeppe
AU - Hansen, Stinus Gadegaard
AU - Brandt, Frans
AU - Nygaard, Birte
AU - Watt, Torquil
AU - Hegedüs, Laszlo
AU - Bonnema, Steen Joop
N1 - Publisher Copyright: © 2024 the author(s)
PY - 2024
Y1 - 2024
N2 - Purpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after 6 weeks, and after 3, 6, 12, and 18 months. Results: In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 (95% CI: 24.5–33.6) and 28.0 (24.5–33.1), respectively; P = 0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 (95% CI: 1512–2512) vs 2344 kIU/L (1862–2951); P = 0.016) but did not influence LT4 dosage or free triiodothyronine–free thyroxine ratio. Conclusion: In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.
AB - Purpose: We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479). Methods: We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after 6 weeks, and after 3, 6, 12, and 18 months. Results: In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 (95% CI: 24.5–33.6) and 28.0 (24.5–33.1), respectively; P = 0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 (95% CI: 1512–2512) vs 2344 kIU/L (1862–2951); P = 0.016) but did not influence LT4 dosage or free triiodothyronine–free thyroxine ratio. Conclusion: In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.
KW - autoimmune thyroiditis
KW - health-related quality of life
KW - hypothyroidism
KW - selenium supplementation
U2 - 10.1530/ETJ-23-0175
DO - 10.1530/ETJ-23-0175
M3 - Journal article
C2 - 38215286
AN - SCOPUS:85184826245
VL - 13
JO - European Thyroid Journal
JF - European Thyroid Journal
SN - 2235-0640
IS - 1
M1 - e230175
ER -
ID: 382992732